TerminatedPhase 1ketamine
Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects
Sponsored by Pfizer
NCT ID
NCT01244880
Target Enrollment
4 participants
Start Date
2011-04
Est. Completion
2012-08
About This Study
To evaluate whether PF-02545920 reduces the effects of ketamine on brain activation during causal learning as measured by fMRI compared to placebo in healthy human subjects, and to evaluate whether behavioral measures of abnormal causal learning under ketamine are reduced by treatment with PF 02545920.
Conditions Studied
Interventions
- •Saline
- •PF-02545920
- •Ketamine
- •PF-02545920
- •Saline
- •Placebo
- •Ketamine
- •Placebo
Eligibility
Age:21 Years - 45 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 21 and 45 years, inclusive. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests). * Right handed as determined by handedness questionnaire. * Able to read and write English as a primary language. Exclusion Criteria: * Female subjects who are pregnant or breastfeeding. * Any evidence of significant psychosis-like symptoms. * Known sensitivity to ketamine.
Study Locations (3)
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States